Health / WORLD

Anvisa bans sales of irregular medicines in Brazil

The bans cover insulin distributed without authorization, an improperly compounded product and unregistered peptides, as well as two medicine batches with quality issues.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

Brazil’s health regulator Anvisa banned the sale of several irregular medicines on October 6. The measures cover insulin glargine distributed by a company without authorization, a compounded medicine marketed to the public without prescriptions, and unregistered peptides.

Anvisa also reported a manufacturer’s voluntary recall of one Imaavy batch and ordered a recall of one Lizbi antibiotic batch after confirming loss of sterility linked to compromised packaging. This account reports regulatory actions and is not individual treatment advice.

Data

Table

Medicines prohibited or recalled

Products and action types in Anvisa’s October 6, 2026 notice.

Insulin glargine 3 mL/100 IU, Costa MarSale of all lots prohibited; distributor lacked authorization.
Vermefree compounded medicine, Sintonia PharmaSale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.
Unregistered peptides listed in noticeSale, manufacture, distribution, advertising, transport and use prohibited.
Imaavy batch JNYJ1201Voluntary recall reported; possible glass particles in vials.
Lizbi batch 0000207107Recall ordered after confirmed sterility loss linked to compromised primary packaging.
Methodology

The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • Brazil · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
    • Explicit preserved editorial country/region; no city or national centroid inferredwww.gov.br ↗
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

Egypt medical-professions risk fund reviews compensation and investments

Health Minister Khaled Abdel Ghaffar chaired the seventh board meeting of the Medical Professions Risk Compensation Fund on October 6. The board reviewed the fund’s finances, compensation payments and investment plan through the end of August 2026.

Egypt State Information Service, citing the Ministry of Health and Population2 min read Data included